|Bid||28.00 x 1000|
|Ask||30.75 x 1100|
|Day's Range||29.06 - 29.74|
|52 Week Range||22.80 - 52.95|
|Beta (3Y Monthly)||1.73|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 28, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||48.83|
SOUTH PLAINFIELD, N.J. , Feb. 14, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Company will host a webcast conference call to report its fourth quarter and year end ...
SOUTH PLAINFIELD, N.J., Feb. 13, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (PTCT) today announced the launch of the fifth annual STRIVE grant award program for Duchenne Muscular Dystrophy. The STRIVE Awards provide funds to patient advocacy organizations around the world to develop unique and collaborative programs that make meaningful contributions to the rare disease community. Since its inception, STRIVE has supported more than 20 programs that have directly impacted the lives of people living with Duchenne, addressing some of the greatest areas of unmet need.
In its inaugural year, PRIORITY will fund programs designed to improve Duchenne screening in infants and support earlier diagnosis of this progressive, muscle-wasting disease. "As a research-driven, patient-centric company, it's important to PTC that we support the efforts of clinicians and researchers who share our passion for improving the clinical care of people with rare, genetic disorders," said Dr. Claudio Santos, Senior Vice President, Global Medical Affairs, PTC Therapeutics.
A look at the shareholders of PTC Therapeutics, Inc. (NASDAQ:PTCT) can tell us which group is most powerful. Insiders often own a large chunk of younger, smaller, companies while huge Read More...
NEW YORK, Jan. 28, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
SOUTH PLAINFIELD, N.J., Jan. 25, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (PTCT) today announced that on January 22, 2019 it approved non-statutory stock options to purchase an aggregate of 170,050 shares of its common stock to 24 new employees. The awards were made pursuant to the NASDAQ inducement grant exception as a component of the new hires' employment compensation. The inducement grants were approved by PTC's Compensation Committee on January 22, 2019 and are being made as an inducement material to each employee's acceptance of employment with the Company in accordance with NASDAQ Listing Rule 5635(c)(4).
All of the shares in the offering are to be sold by PTC. In addition, PTC has granted the underwriter an option for a period of 30 days to purchase up to an additional 1,008,000 shares of common stock at the public offering price, less the underwriting discount. RBC Capital Markets is acting as the sole book-running manager for the offering. An automatically effective shelf registration statement on Form S-3 relating to the shares of common stock offered in the public offering has been filed with the Securities and Exchange Commission (the "SEC") and is available on the SEC's website at www.sec.gov.
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peak (Biotech stocks hitting 52-week highs on Jan. 22) Veracyte Inc (NASDAQ: VCYT ) Down In The Dumps (Biotech ...
SOUTH PLAINFIELD, N.J., Jan. 22, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (PTCT) announced today that it is commencing a public offering of $200 million of shares of its common stock. PTC intends to grant the underwriter an option for a period of 30 days to purchase up to an additional $30 million of shares of common stock. RBC Capital Markets is acting as the sole book-running manager for the offering.
SOUTH PLAINFIELD, N.J. , Jan. 7, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the promotion of Dr. Mark Pykett to Chief Scientific Officer and Dr. Neil Almstead to Chief Technical ...
SOUTH PLAINFIELD, N.J., Jan. 7, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (PTCT) today provided a corporate update, which will be detailed as part of the company's presentation at the 37th Annual J.P. Morgan Healthcare Conference on Tuesday, January 8th at 5:00 p.m. PT. The presentation will be webcast live on the Events and Presentations page under the investors' section of PTC Therapeutics' website at www.ptcbio.com. PTC plans to submit a BLA with the FDA followed by an MAA in Europe for the AADC deficiency gene therapy program in 2H 2019 with expected launch in 2020.
An activist hedge fund, Praesidium Investment Management, was founded a decade ago by experienced investors, Kevin Oram and Peter Uddo. Prior to co-founding Praesidium Investment Management, Kevin Oram, a Chartered Financial Analyst, was employed at Sanford C. Bernstein, where he worked as a Senior Analyst, Senior Vice-President, and was in charge of investments in the […]
SOUTH PLAINFIELD, N.J. , Jan. 2, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company update at the J.P. Morgan Healthcare Conference on Tuesday, ...
SOUTH PLAINFIELD, N.J., Dec. 18, 2018 /PRNewswire/ -- PTC Therapeutics, Inc. (PTCT) today announced the appointment of Emma Reeve and Stephanie Okey to the Company's Board of Directors. Ms. Reeve currently serves as the Chief Financial Officer of Constellation Pharmaceuticals, Inc., a publicly-traded company, and will enhance the financial expertise of the Board. Ms. Okey most recently served as the Senior Vice President, Head of North America, Rare Diseases and U.S. General Manager, Rare Disease Business Unit at Genzyme and brings decades of experience launching and commercializing rare and orphan disease products.
Stuart Peltz became the CEO of PTC Therapeutics, Inc. (NASDAQ:PTCT) in 1998. First, this article will compare CEO compensation with compensation at similar sized companies. Then we'll look at a Read More...
David Kim’s Ghost Tree Capital is a health-care oriented hedge fund with a headquarter in New York. It was founded five years ago, back in 2013, by Ken Greenberg, Matt Diaz (Trader), Brian Kim (Senior Analysts), and of course David Kim. This large advisory firm provides portfolio management services for pooled investment vehicles and pension funds. David […]
How do you pick the next stock to invest in? One way would be to spend hours of research browsing through thousands of publicly traded companies. However, an easier way is to look at the stocks that smart money investors are collectively bullish on. Hedge funds and other institutional investors usually invest large amounts of […]